Bernard Malavaud
Overview
Explore the profile of Bernard Malavaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
2135
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uleri A, Baboudjian M, Pasticier G, Basset V, Cordier G, Malavaud B, et al.
Minerva Urol Nephrol
. 2025 Feb;
PMID: 39932698
Postoperative complications remain a significant challenge in surgical care. This study assessed the ability of the BETTY score, a novel user-friendly scoring system, to predict postoperative outcomes in a large...
2.
Fallara G, Belladelli F, Robesti D, Malavaud B, Tholomier C, Mokkapati S, et al.
Urol Oncol
. 2025 Jan;
43(3):188.e9-188.e17.
PMID: 39788823
Objectives: Survival outcomes of patients with metastatic urothelial carcinoma (mUC) are still suboptimal and strategies to enhance response to immune-oncology (IO) compounds are under scrutiny. In preclinical studies, it has...
3.
Couchoux T, Jaouen T, Melodelima-Gonindard C, Baseilhac P, Branchu A, Arfi N, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):1113-1122.
PMID: 38493072
Background And Objective: Prostate multiparametric magnetic resonance imaging (MRI) shows high sensitivity for International Society of Urological Pathology grade group (GG) ≥2 cancers. Many artificial intelligence algorithms have shown promising...
4.
Ploussard G, Barret E, Fiard G, Lenfant L, Malavaud B, Giannarini G, et al.
Eur Urol Oncol
. 2024 Feb;
7(5):1080-1087.
PMID: 38403523
Background: Recent guidelines favor transperineal (TP) prostate biopsies over the transrectal (TR) approach due to a reduced sepsis risk. Yet, evidence from controlled trial comparing both approaches within the MRI-targeted...
5.
The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma
Contieri R, Martini A, Mertens L, Giannatempo P, Hurle R, Witjes J, et al.
Eur Urol Focus
. 2024 Jan;
10(4):662-665.
PMID: 38199886
Bladder cancer is a significant global health concern owing to its prevalence, negative impact on quality of life, and high treatment costs. Treatment for metastatic urothelial carcinoma (mUC) traditionally relies...
6.
Calleris G, Filleron T, Kesch C, Roubaud G, Pradere B, Cabarrou B, et al.
Eur Urol Oncol
. 2023 Oct;
7(3):494-500.
PMID: 37806843
Background: High-risk prostate cancer (PCa) patients frequently experience recurrence and progression after radical prostatectomy (RP). Neoadjuvant androgen deprivation therapy (ADT) has not demonstrated a clear oncological benefit and is not...
7.
Martini A, Fallara G, Ploussard G, Malavaud B
Lancet Oncol
. 2023 Oct;
24(10):1056-1057.
PMID: 37797626
No abstract available.
8.
Teoh J, DAndrea D, Gallioli A, Yanagisawa T, MacLennan S, Nicoletti R, et al.
World J Urol
. 2023 Aug;
41(10):2599-2606.
PMID: 37584691
Purpose: To learn about the history and development of en bloc resection of bladder tumour (ERBT), and to discuss its future directions in managing bladder cancer. Methods: In this narrative...
9.
Fallara G, Robesti D, Raggi D, Montorsi F, Necchi A, Cooperberg M, et al.
Eur Urol Open Sci
. 2023 May;
52:40-43.
PMID: 37182120
Patient Summary: A recent trial showed that for metastatic prostate cancer that does not respond to hormone treatment, combined therapy with two drugs (olaparib and abiraterone) may prolong survival free...
10.
Touzani A, Fiard G, Barret E, Renard-Penna R, Salin A, Pradere B, et al.
Eur Urol Open Sci
. 2022 Oct;
45:76-80.
PMID: 36217451
PERFECT is a multicentre randomised controlled clinical trial that evaluates the efficiency of fusion magnetic resonance imaging-targeted biopsies in the transperineal (TP) versus transrectal (TR) approach in terms of the...